If Bayer desires to sublicense rights to Commercialize a Licensed Product in the United States and/or three (3) or more of the European Major Markets to a Third Party, such sublicensing shall be subject to prior consultation with and prior written consent of Licensor, such consent to not be unreasonably withheld.